ValiRx Regulatory News (VAL)

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Total Voting Rights

London, UK 1 September 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company today updated its total voting rights disclosure position.

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, the total number of Ordinary Shares in issue will be 56,854,039. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

The figure of 56,854,039 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

As announced on 28 August 2020, application has been made to the London Stock Exchange to admit the 250,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 3 September 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.

Following admission of the 250,000 new ordinary shares to trading on AIM on or around 3 September 2020, the Company's total issued share capital will comprise 57,104,039 ordinary shares of 0.1 pence each.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact: